BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 29677384)

  • 1. Risk factors and long-term outcomes of pediatric liver transplant recipients with chronic high Epstein-Barr virus loads.
    Kamei H; Ito Y; Kawada J; Ogiso S; Onishi Y; Komagome M; Kurata N; Ogura Y
    Transpl Infect Dis; 2018 Aug; 20(4):e12911. PubMed ID: 29677384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of chronic Epstein-Barr virus infection on the liver graft of pediatric liver transplant recipients: A retrospective observational study.
    Shizuku M; Kamei H; Yoshizawa A; Ito Y; Ogura Y; Yoshikawa J; Kurata N; Jobara K; Kodera Y
    Transpl Infect Dis; 2021 Oct; 23(5):e13731. PubMed ID: 34500501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.
    Chen HS; Ho MC; Hu RH; Wu JF; Chen HL; Ni YH; Hsu HY; Jeng YM; Chang MH
    J Formos Med Assoc; 2019 Sep; 118(9):1362-1368. PubMed ID: 30612881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
    Ganschow R; Schulz T; Meyer T; Broering DC; Burdelski M
    J Pediatr Gastroenterol Nutr; 2004 Feb; 38(2):198-203. PubMed ID: 14734884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
    Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus DNA monitoring in serum and whole blood in pediatric liver transplant recipients who do or do not discontinue immunosuppressive therapy.
    Kullberg-Lindh C; Saalman R; Olausson M; Herlenius G; Lindh M
    Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28039929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Scheduled Program of Molecular Screening for Epstein-Barr Virus Decreases the Incidence of Post-transplantation Lymphoproliferative Disease in Pediatric Liver Transplantation.
    Soriano-López DP; Alcántar-Fierros JM; Hernández-Plata JA; González-Jorge AL; Velázquez-Ramos S; Flores-Hernández MA; Fuentes V; Castañeda P; Nieto J; Sánchez JL; López B; Valencia-Mayoral P; Varela-Fascinetto G
    Transplant Proc; 2016 Mar; 48(2):654-7. PubMed ID: 27110023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
    Narkewicz MR; Green M; Dunn S; Millis M; McDiarmid S; Mazariegos G; Anand R; Yin W;
    Liver Transpl; 2013 Jul; 19(7):730-40. PubMed ID: 23696264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-lasting chronic high load carriage of Epstein-Barr virus is more common in young pediatric renal transplant recipients.
    Ladfors SW; Lindahl JK; Hansson S; Brandström P; Andersson R; Jertborn M; Lindh M; Woxenius S; Friman V
    Pediatr Nephrol; 2020 Mar; 35(3):427-439. PubMed ID: 31802220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus DNAemia in Iranian liver transplant recipients and assessment of its variation in posttransplant lymphproliferative disorder patients by quantitative polymerase chain reaction assay.
    Jamalidoust M; Geramizadeh B; Pouladfar G; Namayandeh M; Asaie S; Aliabadi N; Nikeghbalian S; Ziyaeyan M
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():306-11. PubMed ID: 25894179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome.
    Holmes RD; Orban-Eller K; Karrer FR; Rowe DT; Narkewicz MR; Sokol RJ
    Transplantation; 2002 Aug; 74(3):367-72. PubMed ID: 12177616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
    G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology and outcome of chronic high Epstein-Barr viral load carriage in pediatric kidney transplant recipients.
    Yamada M; Nguyen C; Fadakar P; Ganoza A; Humar A; Shapiro R; Michaels MG; Green M
    Pediatr Transplant; 2018 May; 22(3):e13147. PubMed ID: 29411474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease.
    Carpentier L; Tapiero B; Alvarez F; Viau C; Alfieri C
    J Infect Dis; 2003 Dec; 188(12):1853-64. PubMed ID: 14673764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus associated smooth muscle tumors in solid organ transplant recipients: Incidence over 31 years at a single institution and review of the literature.
    Stubbins RJ; Alami Laroussi N; Peters AC; Urschel S; Dicke F; Lai RL; Zhu J; Mabilangan C; Preiksaitis JK
    Transpl Infect Dis; 2019 Feb; 21(1):e13010. PubMed ID: 30298678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of Epstein-Barr virus load and killer T cells in pediatric renal transplant recipients.
    Sato T; Fujieda M; Maeda A; Tanaka E; Miyamura M; Chikamoto H; Hisano M; Akioka Y; Ishiura Y; Dohno S; Hattori M; Wakiguchi H
    Clin Nephrol; 2008 Nov; 70(5):393-403. PubMed ID: 19000539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreasing the Epstein-Barr virus load by adjusting the FK506 blood level.
    Orii T; Ohkohchi N; Satomi S; Hoshino Y; Kimura H
    Transpl Int; 2002 Nov; 15(11):529-34. PubMed ID: 12461655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic and virologic analyses in pediatric liver transplant recipients with chronic high Epstein-Barr virus loads.
    Gotoh K; Ito Y; Ohta R; Iwata S; Nishiyama Y; Nakamura T; Kaneko K; Kiuchi T; Ando H; Kimura H
    J Infect Dis; 2010 Aug; 202(3):461-9. PubMed ID: 20560768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children.
    Wu JF; Ho MC; Ni YH; Chen HL; Lu CY; Hsu HY; Lee PH; Chang MH
    Transplantation; 2009 Mar; 87(5):758-62. PubMed ID: 19295323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.